Articles of note for people dealing with pituitary disease and related conditions.
The latest from pharmaceutical companies and healthcare organizations
Brief, insightful commentary from Dr. Lewis Blevins on issues of relevance to pituitary disease.
Same Tumor, Scarier Name: What the PitNET Reclassification Means for You
This is my conversation with Dr. Ken Ho, Professor at St. Vincent's Hospital, Sydney and Garvan Institute of Medical Research, Sydney, Australia, on why a single word could change how pituitary patients are treated, and why leading endocrinologists are asking the WHO to reconsider. In this podcasts interview he walks through why he and colleagues at the International Pituitary Society object to the WHO (World Health Organization) reclassification of pituitary adenomas as "PitNETs" (pituitary neuroendocrine tumors).
More from Endo 2026 and the fast moving world of pituitary medicine
I sat down with Dr. Leena Shahla, medical director of the Duke Pituitary Center to talk about the latest developments from ENDO 2026. Many in of our readers will remember her from an earlier Pituitary World News Podcast conversation with our co-founder, Dr. Lewis Blevins, on the tricky business of distinguishing pseudo-Cushing’s from the real thing. This time, the focus was the fast-moving world of acromegaly therapy.
Worth noting:
Crinetics Pharmaceuticals, launches a new resource, Everyday Advocacy, with leading patient groups. Read more
From Debiopharm, read about Oxtend™ 3 clinical trial for acromegaly for a long term (3-month) octreotide treatment. More information here.
From Camurus more information on a new treatment option for acromegaly. Read more here
From Crinetics Pharmaceuticals, FDA approves Crinetics PALSONIFY™ for adults with acromegaly . Read more
Recordati announces FDA approval of ISTURISA® new indication in the U.S. to treat endogenous hypercortisolemia in patients with Cushing’s syndrome,- Learn more here
New support site from Chiesi; Rethink acromegaly
Chiesi relaunches a patient-facing website for Mycapssa.
Content for physicians and healthcare professionals.
Join a drug trial. Find out how. Here’s a partial list of studies.
Latest trends and a roundup of health and wellness news
The Podcast
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D. Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Live Talk on Demand
At ENDO 2026, Dr. Richard Auchus of the University of Michigan shares his perspectives on the connection between type 2 diabetes and hard-to-control hypertension and high cortisol in Corcept Therapeutics’ landmark studies. The interview covers two related studies investigating how often “common” diseases—difficult-to-control diabetes and hypertension are actually being driven by undiagnosed adrenal dysfunction, particularly mild, clinically significant cortisol excess from adrenal adenomas.
Our live talk sessions of the pituitary and adrenal podcasts continue with this extremely informational conversation on hypothalamic obesity. If you are interested in learning more about his devastating disorder, please listen to Dr. Blevins as he shares his insights and extensive expertise on its causes, new treatments, and latest developments.
Apple Podcasts
Spotify
Amazon Music
Google PodcastsEvents
Save the date!
